Loading…
Radiopharm Theranostics Limited is projected to rise to $3.01 by 2027, a +3% move from its current price of $2.92. RADX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/5/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 6 | $2.80 | $2.92 | $3.04 | +0.05% |
| Aug 7 | $2.76 | $2.92 | $3.10 | +0.09% |
| Aug 8 | $2.73 | $2.92 | $3.14 | +0.14% |
| Aug 9 | $2.70 | $2.93 | $3.17 | +0.18% |
| Aug 10 | $2.67 | $2.93 | $3.21 | +0.23% |
| Aug 11 | $2.65 | $2.93 | $3.23 | +0.28% |
| Aug 12 | $2.63 | $2.93 | $3.26 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.63 | $2.93 | $3.26 | +0.32% |
| Week 2 | $2.52 | $2.94 | $3.42 | +0.64% |
| Week 3 | $2.45 | $2.95 | $3.55 | +0.97% |
| Week 4 | $2.39 | $2.96 | $3.67 | +1.29% |
| Week 5 | $2.33 | $2.97 | $3.77 | +1.62% |
| Week 6 | $2.29 | $2.98 | $3.87 | +1.95% |
| Week 7 | $2.25 | $2.99 | $3.97 | +2.27% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Radiopharm Theranostics Limited is a clinical-stage radiotherapeutics company focusing on radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
The company was incorporated in 2021 and is based in Carlton, Australia. It has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. Radiopharm Theranostics is categorized under Healthcare and operates in the field of radiopharmaceutical diagnostics and therapeutics.
Radiopharm Theranostics Limited trades at $3.15 per share and has a market capitalization of $24.83M. It is currently ranked 4794th. These metrics place RADX among a small-cap segment with a modest market footprint.
The forecast shows a path from 2026 with a 30-day view where the min, avg, and max are $3.15, $3.15, and $4.76 respectively, with an ROI of 0 and neutral sentiment. By 2050, the average price is projected at $15.04 with a max of $34.45 and an ROI of 377.3%, with bullish sentiment in the long horizon.
Overall, the price outlook traces a potential longer-term upside path, including notable gains implied in later years through 2050, while near-term values hover near the current level.
A major floor 33.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 51.7% above — a clean break opens room to run.
A major ceiling 69.5% above — clearing it would confirm fresh momentum.
Key RADX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RADX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.07 | Sell | $3.09 | Sell |
| MA 10 | $3.33 | Sell | $3.32 | Sell |
| MA 20 | $3.83 | Sell | $3.64 | Sell |
| MA 50 | $4.15 | Sell | $4.02 | Sell |
| MA 100 | $4.33 | Sell | $4.30 | Sell |
| MA 200 | $4.68 | Sell | $4.77 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 24.46 | Buy |
| Stoch RSI (14) | 7.23 | Buy |
| CCI (20) | -105.46 | Sell |
| Williams %R (14) | -96.69 | Info |
| MACD (12,26,9) | -0.11 | Sell |
| ROC (12) | -30.61 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 3.31 | Buy |
| TRIX (15) | -0.81 | Sell |
| Awesome (5,34) | -0.94 | Sell |
| Ultimate (7,14,28) | 15.56 | Buy |
| Momentum (10) | -1.32 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 2.91 | Buy |
| ADX (14) | 26.62 | Sell |
| ATR (14) | 0.12 | Info |
The 30-day technical picture shows sentiment is NEUTRAL, with RSI(14) at 20. The stock trades below the 50-day and 200-day moving averages, at $4.31 and $4.78 respectively. Immediate support is at $3.15 and resistance at $4.45, with the 30-day price range between $2.34 and $4.24.
Annualized volatility is high, at 90%, underscoring potential for wide swings in either direction.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.92 | $2.92 | $4.32 | 0% | Neutral | |
| $2.30 | $3.01 | $4.23 | +3% | Neutral | |
| $2.85 | $3.91 | $5.79 | +34% | Bullish | |
| $3.19 | $4.54 | $7.00 | +55% | Bullish | |
| $3.09 | $4.55 | $7.26 | +56% | Bullish | |
| $3.01 | $4.57 | $7.50 | +56% | Bullish | |
| $2.67 | $4.18 | $7.03 | +43% | Bullish | |
| $2.65 | $4.26 | $7.34 | +46% | Bullish | |
| $2.76 | $4.55 | $8.01 | +56% | Bullish | |
| $3.06 | $5.18 | $9.29 | +77% | Bullish | |
| $2.97 | $5.64 | $10.98 | +93% | Bullish | |
| $6.23 | $13.85 | $30.23 | +374% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.92 | $2.92 | $3.74 | +0.00% |
| September 2026 | $2.57 | $3.08 | $3.83 | +5.61% |
| October 2026 | $2.51 | $3.04 | $3.84 | -1.27% |
| November 2026 | $2.64 | $3.22 | $4.12 | +5.88% |
| December 2026 | $2.72 | $3.35 | $4.32 | +3.77% |
Click any year to see its month-by-month RADX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, RADX could reach as high as $4.32, with a base case around $2.92 and support toward $2.92 — roughly 0% from $2.92. Price action looks broadly range-bound.
Expect RADX to range from $2.30 to $4.23 through 2027. The $3.01 average target implies a +3% move from current prices. That is up +3% on the projected 2026 average. A consolidation phase looks the most probable path here.
The RADX price prediction for 2028 points to an average of $3.91 (low $2.85, high $5.79) — a potential gain of +34% on today's $2.92. Momentum favours further upside here.
In 2029, RADX is projected to trade between $3.19 and $7.00, averaging $4.54 — a potential gain of +55% from today's $2.92. That is up +16% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Radiopharm Theranostics Limited's 2030 outlook centres on $4.55, within a $3.09 to $7.26 range. That is up 0% on the projected 2029 average. That marks a +56% change versus current levels. Momentum favours further upside here.
By 2031, RADX could reach as high as $7.50, with a base case around $4.57 and support toward $3.01 — roughly +56% from $2.92. Buyers look set to stay in control over this stretch.
Expect RADX to range from $2.67 to $7.03 through 2032. The $4.18 average target implies a +43% move from current prices. That is -9% versus the projected 2031 average. Momentum favours further upside here.
The RADX price prediction for 2033 points to an average of $4.26 (low $2.65, high $7.34) — a potential gain of +46% on today's $2.92. Buyers look set to stay in control over this stretch.
In 2034, RADX is projected to trade between $2.76 and $8.01, averaging $4.55 — a potential gain of +56% from today's $2.92. That is up +7% on the projected 2033 average. Momentum favours further upside here.
Radiopharm Theranostics Limited's 2035 outlook centres on $5.18, within a $3.06 to $9.29 range. That is up +14% on the projected 2034 average. That marks a +77% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, RADX could reach as high as $10.98, with a base case around $5.64 and support toward $2.97 — roughly +93% from $2.92. Momentum favours further upside here.
Expect RADX to range from $6.23 to $30.23 through 2050. The $13.85 average target implies a +374% move from current prices. That is up +145% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in RADX today (≈ 342.465753 RADX) could be worth
$4,741.61
+$3,741.61 (+374%) by 2050 · US Dollar
Based on the average projected RADX price of $13.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RADXwould be worth at today's price.
$1,000 invested in RADX on Aug 5, 2025 (≈ 190.47619 RADX) would be worth
$556.19
-$443.81 (-44.4%) today · 0.56× · US Dollar
Based on a RADX entry price of $5.25 vs. today's $2.92.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.15 | $926.98 | -7.3% |
| 1 month ago | $4.35 | $671.26 | -32.9% |
| 3 months ago | $4.15 | $703.61 | -29.6% |
| 6 months ago | $4.97 | $587.53 | -41.2% |
| 1 year ago | $5.25 | $556.19 | -44.4% |
| All time (1.7y) ago | $17.67 | $165.25 | -83.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RADX forecast.
Our base-case forecast reaches $5.80 around 2050.
Implied market cap at $5.80: $45.72M
Looking at the multi-year forecast, 2026 projects an average price of $3.15 (min $3.15, max $4.76) with ROI 0 and neutral sentiment. In 2027 the average is $3.18 (min $2.39, max $4.56) with ROI 0.9 and neutral sentiment.
From 2028 onward, the outlook turns bullish, with 2028 average $4.33 and 2029 average $5.01, followed by 2030 at $4.97 and 2031 at $5.04. The sequence continues with 2032 at $4.48, 2033 at $4.55, 2034 at $4.95, and 2035 at $5.53, all titled with bullish sentiment and rising ROI to 75.6% by 2035.
The long horizon shows further upside—by 2040 the average is projected at $6.07 (max $12.32) with ROI 92.8% and bullish sentiment, and by 2050 the average reaches $15.04 (max $34.45) with ROI 377.3% and bullish sentiment. These figures are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $4.97 with a minimum of $3.27 and a maximum of $8.15, and a projected ROI of 57.6% with bullish sentiment.
Forecasts indicate neutral sentiment in 2026 and 2027, turning bullish from 2028 onward, with an average price rising to $15.04 by 2050 and a projected ROI of 377.3%. These are estimates, not guarantees.
Yes. The 2035 forecast lists a maximum of $10.30, indicating a potential to exceed $10 during that year based on the provided projections.
The 2040 forecast shows an average price of $6.07 and a maximum of $12.32, with a projected ROI of 92.8% and bullish sentiment.
The current price is $3.15 and the market capitalization is $24.83M, with a rank of 4794.
Radiopharm Theranostics Limited Community Discussion
0Share your Radiopharm Theranostics Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.